Paper Details

  1. Home
  2. Paper Details

An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination.

Author: AlfieriFernando, FelipeCláudia R, FrancoMarcelo, GarciaRiberto, HanzawaNilva M, MachadoPaula G P, Medina-PestanaJosé O, ParkSung I, SilvaHélio T

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Sirolimus, in combination with reduced cyclosporine exposure, is effective in preventing acute rejection in renal transplant recipients. It also reduces the incidence of rejection compared to azathioprine with standard cyclosporine doses.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The ability of sirolimus (SRL), in combination with reduced exposure of cyclosporine, was investigated to prevent acute rejection and associated side effects. METHODS: Between June 1999 and February 2000, 70 recipients of primary one-haplotype living-related donor renal allografts were ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1399-0012.2004.00113.x

データ提供：米国国立医学図書館（NLM）

Sirolimus: A New Oasis in Renal Transplant Management?

The field of [organ transplantation] is constantly evolving, with researchers seeking innovative ways to improve graft survival and minimize complications. This study explores the efficacy of [sirolimus (SRL)] in combination with reduced cyclosporine exposure as a potential alternative to [azathioprine (AZA)] in preventing [acute rejection] in renal transplant recipients. Using [a randomized controlled trial], the researchers compared the outcomes of SRL and AZA regimens in a cohort of [70] patients.

A Shifting Landscape in Renal Transplant

The study revealed that SRL, when used in combination with reduced cyclosporine, resulted in a [significantly lower incidence] of acute rejection compared to AZA. This suggests that SRL might offer a [more effective] approach to preventing rejection, leading to improved graft survival and reduced need for immunosuppressive medications.

Navigating the Sands of Renal Transplant

While SRL holds promise, it's important to acknowledge that it may also be associated with an increased risk of [hyperlipidemia]. Therefore, careful monitoring of lipid levels and appropriate interventions are crucial for patients receiving SRL therapy.

Dr. Camel's Conclusion

Sirolimus, in combination with reduced cyclosporine, demonstrates potential as a promising alternative to azathioprine for preventing acute rejection in renal transplant recipients. However, the risk of hyperlipidemia necessitates close monitoring and management of lipid levels.

Date :
  1. Date Completed 2004-05-20
  2. Date Revised 2019-11-08
Further Info :

Pubmed ID

15108768

DOI: Digital Object Identifier

10.1111/j.1399-0012.2004.00113.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.